ArticleHaematologica2013

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.

Franck E Nicolini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.